Table 2.
Pooled results from 2 TTH trials in patients over 4 h for AAC-130, APAP, and placebo [74]
Measure | AAC-130 (n = 1369) | APAP (n = 1376) | Placebo (n = 689) |
---|---|---|---|
SPID | 5.30 ± 0.06a,b | 4.70 ± 0.07b | 3.95 ± 0.10 |
%SPID | 57.6 ± 0.7a,b | 50.6 ± 0.7b | 42.7 ± 1.0 |
Maximum PID | 1.89 ± 0.02a,b | 1.74 ± 0.02b | 1.53 ± 0.03 |
TOTPAR | 10.52 ± 0.10a,b | 9.38 ± 0.10b | 8.20 ± 0.16 |
Maximum PAR | 3.42 ± 0.02a,b | 3.14 ± 0.03b | 2.81 ± 0.04 |
Time to pain at least half gone (hours) | 3.01 ± 0.03a,b | 2.73 ± 0.03b | 2.38 ± 0.05 |
AAC-130, acetaminophen 500 mg, aspirin 500 mg, and caffeine 130 mg per 2-tablet dose; APAP, acetaminophen 1000 mg per 2-tablet dose; SPID, sum of pain intensity differences; PID, pain intensity difference from baseline; TOTAR, total pain relief; PAR, pain relief
Values are mean ± standard error
a P < 0.05 vs APAP
b P < 0.05 vs placebo